Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and …

Background: The randomized phase 3 ASPIRE study demonstrated that the addition of the proteasome inhibitor carfilzomib to Rd resulted in significantly improved progression-free survival (PFS) compared with Rd alone in patients with RRMM (median 26.3 vs 17.6 months; hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.57-0.83; 2-sided P= 0.0001; Stewart AK, et al. N Engl J Med. 2015; 372: 142-52; Table). OS data were immature at the time of the PFS analysis but showed a trend in favor of the KRd group (HR= 0.79). Hereby, results from the planned final analysis of OS in ASPIRE are presented.Methods: Adults with RRMM who received 1─ 3 prior lines of therapy were eligible. Patients were randomized (1: 1) to receive KRd or Rd in 28-day cycles until withdrawal of consent, disease progression, or the occurrence of unacceptable toxicity. Randomization was stratified according to β2-microglobulin level (< …